MICHAEL A DAVIES to Molecular Targeted Therapy
This is a "connection" page, showing publications MICHAEL A DAVIES has written about Molecular Targeted Therapy.
Connection Strength
1.195
-
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
Score: 0.291
-
Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Hematol Oncol Clin North Am. 2014 Jun; 28(3):523-36.
Score: 0.225
-
Overcoming resistance to MAPK pathway inhibitors. J Natl Cancer Inst. 2013 Jan 02; 105(1):9-10.
Score: 0.204
-
Targeted therapy for brain metastases. Adv Pharmacol. 2012; 65:109-42.
Score: 0.191
-
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
Score: 0.098
-
Re-thinking therapeutic development for CNS metastatic disease. Exp Dermatol. 2022 01; 31(1):74-81.
Score: 0.092
-
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell. 2020 12 14; 38(6):829-843.e4.
Score: 0.022
-
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell Melanoma Res. 2020 07; 33(4):527-541.
Score: 0.021
-
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019 11 21; 7(1):319.
Score: 0.021
-
ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Res. 2015 Sep 01; 75(17):3554-67.
Score: 0.015
-
A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
Score: 0.015